Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000

摘要

BackgroundIt is unclear whether individualized treatments based on biological factors have improved the prognosis of recurrent breast cancer. The purpose of this study is to evaluate the survival improvement of patients with recurrent breast cancer after the introduction of third generation aromatase inhibitors (AIs) and trastuzumab.